- Home
- REVBW vs NCL Comparison
REVBW vs NCL Comparison
Compare REVBW & NCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- NCL
- Stock Information
- Founded
- REVBW N/A
- NCL 2013
- Country
- REVBW United States
- NCL United States
- Employees
- REVBW 9
- NCL N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- NCL
- Sector
- REVBW Health Care
- NCL
- Exchange
- REVBW Nasdaq
- NCL Nasdaq
- Market Cap
- REVBW N/A
- NCL N/A
- IPO Year
- REVBW 2020
- NCL 2023
- Fundamental
- Price
- REVBW $0.01
- NCL $0.32
- Analyst Decision
- REVBW
- NCL
- Analyst Count
- REVBW 0
- NCL 0
- Target Price
- REVBW N/A
- NCL N/A
- AVG Volume (30 Days)
- REVBW N/A
- NCL 413.9K
- Earning Date
- REVBW N/A
- NCL 11-19-2024
- Dividend Yield
- REVBW N/A
- NCL N/A
- EPS Growth
- REVBW N/A
- NCL N/A
- EPS
- REVBW N/A
- NCL N/A
- Revenue
- REVBW N/A
- NCL $15,576,857.00
- Revenue This Year
- REVBW N/A
- NCL N/A
- Revenue Next Year
- REVBW N/A
- NCL N/A
- P/E Ratio
- REVBW N/A
- NCL N/A
- Revenue Growth
- REVBW N/A
- NCL 47.13
- 52 Week Low
- REVBW N/A
- NCL $0.15
- 52 Week High
- REVBW N/A
- NCL $1.64
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- NCL 57.41
- Support Level
- REVBW N/A
- NCL $0.25
- Resistance Level
- REVBW N/A
- NCL $0.34
- Average True Range (ATR)
- REVBW 0.00
- NCL 0.04
- MACD
- REVBW 0.00
- NCL 0.00
- Stochastic Oscillator
- REVBW 0.00
- NCL 50.78
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).